Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Capital Expenditures (2016 - 2025)

Cytosorbents (CTSO) has disclosed Capital Expenditures for 14 consecutive years, with $17000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures fell 88.82% year-over-year to $17000.0, compared with a TTM value of $125343.0 through Sep 2025, down 59.63%, and an annual FY2024 reading of $284343.0, down 47.16% over the prior year.
  • Capital Expenditures was $17000.0 for Q3 2025 at Cytosorbents, up from -$213783.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.1 million in Q1 2022 and bottomed at -$1.9 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $256824.8, with a median of $79236.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures soared 845.91% in 2021, then tumbled 1300.42% in 2025.
  • Year by year, Capital Expenditures stood at $1.5 million in 2021, then tumbled by 94.83% to $79236.0 in 2022, then increased by 20.52% to $95497.0 in 2023, then dropped by 27.39% to $69343.0 in 2024, then crashed by 75.48% to $17000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CTSO at $17000.0 in Q3 2025, -$213783.0 in Q2 2025, and $252783.0 in Q1 2025.